Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Immunocore Holdings Plc ADR
(NQ:
IMCR
)
32.86
+0.58 (+1.80%)
Streaming Delayed Price
Updated: 3:48 PM EST, Nov 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Immunocore Holdings Plc ADR
< Previous
1
2
3
4
5
6
Next >
Immunocore to present at upcoming investor conferences
April 04, 2024
From
Immunocore Holdings Limited
Via
GlobeNewswire
Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio
March 13, 2024
One of the primary features of Bill Gates biotech stocks is they are all working towards a cure for HIV and related illnesses.
Via
InvestorPlace
Immunocore presented two posters at CROI 2024
March 05, 2024
From
Immunocore Holdings Limited
Via
GlobeNewswire
Immunocore to present at upcoming investor conferences
March 01, 2024
From
Immunocore Holdings Limited
Via
GlobeNewswire
Key Takeaways From Immunocore Hldgs Analyst Ratings
February 29, 2024
Via
Benzinga
Immunocore Hldgs's Earnings: A Preview
February 27, 2024
Via
Benzinga
Immunocore's Pipeline Is Among The Strongest In Broader Biotech Universe: Analyst
January 05, 2024
H.C. Wainwright analyst Patrick R.
Via
Benzinga
5 Analysts Have This to Say About Immunocore Hldgs
November 20, 2023
Via
Benzinga
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
February 28, 2024
From
Immunocore Holdings Limited
Via
GlobeNewswire
Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial
February 22, 2024
From
Immunocore Holdings Limited
Via
GlobeNewswire
Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024
February 21, 2024
From
Immunocore Holdings Limited
Via
GlobeNewswire
Immunocore Prices Upsized Convertible Senior Notes Offering
January 30, 2024
From
Immunocore Holdings Limited
Via
GlobeNewswire
Analyst Ratings for Immunocore Hldgs
November 02, 2023
Via
Benzinga
Analyst Expectations for Immunocore Hldgs's Future
September 13, 2023
Via
Benzinga
Immunocore Announces Proposed Convertible Senior Notes Offering
January 29, 2024
From
Immunocore Holdings Limited
Via
GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
January 16, 2024
Via
Benzinga
Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
January 05, 2024
Shares of Applied Therapeutics, Inc.
Via
Benzinga
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
January 05, 2024
From
Immunocore Holdings Limited
Via
GlobeNewswire
Immunocore to present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Immunocore Holdings Limited
Via
GlobeNewswire
AGC Biologics to Prepare Late Phase and Commercial Runs for Immunocore
November 20, 2023
--News Direct--
Via
News Direct
Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update
November 07, 2023
From
Immunocore Holdings Limited
Via
GlobeNewswire
Immunocore announces upcoming poster presentations at SITC Annual Meeting 2023 and SMR Congress 2023
November 01, 2023
From
Immunocore Holdings Limited
Via
GlobeNewswire
Immunocore to present at upcoming investor conferences
October 30, 2023
From
Immunocore Holdings Limited
Via
GlobeNewswire
Immunocore presents three-year overall survival data from the KIMMTRAK Phase 3 trial
October 21, 2023
From
Immunocore Holdings Limited
Via
GlobeNewswire
Immunocore announces upcoming presentation and posters at ESMO 2023
October 06, 2023
From
Immunocore Holdings Limited
Via
GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
October 02, 2023
Via
Benzinga
Cancer Focused Immunocore Leads The Way In TCR Therapeutics, Positioned For Success: Analyst Says
September 13, 2023
Needham has initiated coverage on Immunocore Holdings Plc (NASDAQ: IMCR) with a Buy rating and
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 13, 2023
September 13, 2023
Via
Benzinga
Immunocore to present at upcoming investor conferences
September 11, 2023
From
Immunocore Holdings Limited
Via
GlobeNewswire
Institutions are Buying These 3 Stocks and Analysts Agree
September 07, 2023
Rumble (RUM), Immunocore (IMCR), and STMicroelectronics (STM) are attracting increased institutional interest, presenting potential investment opportunities.
Via
MarketBeat
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
